West Pharmaceutical Services, Inc. $WST Shares Sold by Liontrust Investment Partners LLP

Liontrust Investment Partners LLP decreased its holdings in West Pharmaceutical Services, Inc. (NYSE:WST) by 8.0% in the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 336,995 shares of the medical instruments supplier’s stock after selling 29,193 shares during the quarter. Liontrust Investment Partners LLP’s holdings in West Pharmaceutical Services were worth $84,464,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of WST. Brendel Financial Advisors LLC bought a new position in West Pharmaceutical Services during the 4th quarter valued at about $3,742,000. Birch Hill Investment Advisors LLC grew its stake in West Pharmaceutical Services by 11.5% during the fourth quarter. Birch Hill Investment Advisors LLC now owns 152,148 shares of the medical instruments supplier’s stock worth $41,862,000 after buying an additional 15,678 shares during the last quarter. Bank of Nova Scotia grew its stake in West Pharmaceutical Services by 337.8% during the first quarter. Bank of Nova Scotia now owns 65,323 shares of the medical instruments supplier’s stock worth $16,373,000 after buying an additional 50,402 shares during the last quarter. Annex Advisory Services LLC increased its holdings in shares of West Pharmaceutical Services by 8.7% during the fourth quarter. Annex Advisory Services LLC now owns 122,958 shares of the medical instruments supplier’s stock worth $33,831,000 after buying an additional 9,800 shares in the last quarter. Finally, Hsbc Holdings PLC raised its stake in shares of West Pharmaceutical Services by 23.3% in the fourth quarter. Hsbc Holdings PLC now owns 146,872 shares of the medical instruments supplier’s stock valued at $40,425,000 after acquiring an additional 27,745 shares during the last quarter. Institutional investors and hedge funds own 93.90% of the company’s stock.

Analyst Upgrades and Downgrades

WST has been the topic of several recent analyst reports. TD Cowen reissued a “buy” rating on shares of West Pharmaceutical Services in a report on Wednesday, July 15th. Zacks Research upgraded West Pharmaceutical Services from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, May 13th. Stephens reiterated an “overweight” rating and issued a $360.00 price objective on shares of West Pharmaceutical Services in a research report on Tuesday, June 2nd. Morgan Stanley boosted their price objective on West Pharmaceutical Services from $325.00 to $365.00 and gave the stock an “equal weight” rating in a research note on Thursday, July 9th. Finally, Evercore restated an “outperform” rating and set a $425.00 target price on shares of West Pharmaceutical Services in a report on Monday. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and two have issued a Hold rating to the stock. Based on data from MarketBeat, the stock has an average rating of “Buy” and a consensus price target of $364.42.

West Pharmaceutical Services Stock Performance

Shares of West Pharmaceutical Services stock opened at $339.20 on Friday. The company has a debt-to-equity ratio of 0.07, a current ratio of 2.82 and a quick ratio of 2.12. The firm has a market cap of $23.87 billion, a P/E ratio of 43.43, a P/E/G ratio of 2.36 and a beta of 1.16. The firm has a 50 day simple moving average of $339.32 and a 200 day simple moving average of $289.15. West Pharmaceutical Services, Inc. has a fifty-two week low of $223.83 and a fifty-two week high of $386.00.

West Pharmaceutical Services (NYSE:WST) last announced its quarterly earnings data on Thursday, July 23rd. The medical instruments supplier reported $2.37 EPS for the quarter, beating analysts’ consensus estimates of $2.08 by $0.29. The firm had revenue of $872.30 million for the quarter, compared to analyst estimates of $839.98 million. West Pharmaceutical Services had a return on equity of 20.11% and a net margin of 16.98%.The business’s quarterly revenue was up 13.8% compared to the same quarter last year. During the same period last year, the company earned $1.84 EPS. West Pharmaceutical Services has set its Q3 2026 guidance at 2.140-2.240 EPS and its FY 2026 guidance at 8.850-9.050 EPS. Sell-side analysts predict that West Pharmaceutical Services, Inc. will post 8.94 earnings per share for the current fiscal year.

West Pharmaceutical Services Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Wednesday, August 5th. Investors of record on Wednesday, July 29th will be issued a $0.22 dividend. The ex-dividend date is Wednesday, July 29th. This represents a $0.88 annualized dividend and a yield of 0.3%. West Pharmaceutical Services’s dividend payout ratio (DPR) is currently 11.27%.

West Pharmaceutical Services Company Profile

West Pharmaceutical Services, Inc is a global developer and manufacturer of components, systems and services that enable the containment and delivery of injectable drugs. The company focuses on high-quality packaging and delivery solutions for the pharmaceutical and biotech industries, producing primary drug packaging components and specialized drug delivery devices used for vaccines, biologics and other injectable therapies. West is known for its elastomeric closures, seals and polymer components that maintain sterility and compatibility with sensitive drug formulations.

In addition to component manufacturing, West provides engineered delivery systems and support services across the product lifecycle.